Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00617903 · ClinicalTrials.gov registry record · Phase 2

Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea

A Phase 2 study, sponsored by LEO Pharma.

Completed
Registry status
Phase 2
Development phase
83
Enrollment target

NCT00617903 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 83 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00617903, a Phase 2 study, has completed, sponsored by LEO Pharma.

COMPLETED
Registry status
Phase 2
Development phase
83 participants
Enrollment target

Study Summary

This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.

Interventions

  • DRUG Azelaic acid
  • DRUG Vehicle foam

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2008-01
Est. Completion 2008-06
Phase Phase 2

Sponsor

LEO Pharma

65 total trials

What the Registry Record Tells You About NCT00617903

The ClinicalTrials.gov registry entry for NCT00617903 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Azelaic acid is the first listed.

NCT00617903 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00617903 about?

NCT00617903 is a clinical study titled "Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea". This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.

What is the current status of trial NCT00617903?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2008-01. Estimated completion is 2008-06.

What interventions are being tested in trial NCT00617903?

The interventions under investigation include: Azelaic acid (DRUG), Vehicle foam (DRUG).

Who is sponsoring clinical trial NCT00617903?

This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.